Pharmacological interventions on smoking cessation: A systematic review and network meta-analysis
Conclusion: Most pharmacological interventions demonstrated a benefit in smoking cessation compared with placebo, whether monotherapy or combination therapy. Moreover, confirmed evidence suggested that some combination treatments, such as varenicline plus bupropion and nicotine replacement therapy plus mecamylamine have a higher probability of being the best smoking cessation in (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - October 24, 2022 Category: Drugs & Pharmacology Source Type: research
Patient survey examining the experience of care of a hospital-based opt-out tobacco dependency treatment service (the CURE Project)
CONCLUSION: These results suggest this hospital-based, opt-out tobacco dependency treatment service delivers high-quality experience of care and meets the needs of the patients it serves. It also highlights the opportunity to enhance outcomes by providing access to NICE recommended most-effective interventions (varenicline, vaping and combination nicotine replacement therapy) and providing flexible, individualised discharge pathways.PMID:36216401 | DOI:10.1136/bmjresp-2022-001334 (Source: Cancer Control)
Source: Cancer Control - October 10, 2022 Category: Cancer & Oncology Authors: Lynn Hryhorskyj Freya Howle Kathryn Groom Ryan Moore Hannah Clegg David Shackley Cheryl Pearce Monique Baugh Michael Rutherford Helen Huddart Alyshia Mawson Emily Manley Kath Hewitt Jane Coyne Elizabeth Benbow Andrea Crossfield Rachael L Murray Matthew Ev Source Type: research
Patient survey examining the experience of care of a hospital-based opt-out tobacco dependency treatment service (the CURE Project)
CONCLUSION: These results suggest this hospital-based, opt-out tobacco dependency treatment service delivers high-quality experience of care and meets the needs of the patients it serves. It also highlights the opportunity to enhance outcomes by providing access to NICE recommended most-effective interventions (varenicline, vaping and combination nicotine replacement therapy) and providing flexible, individualised discharge pathways.PMID:36216401 | DOI:10.1136/bmjresp-2022-001334 (Source: Respiratory Care)
Source: Respiratory Care - October 10, 2022 Category: Respiratory Medicine Authors: Lynn Hryhorskyj Freya Howle Kathryn Groom Ryan Moore Hannah Clegg David Shackley Cheryl Pearce Monique Baugh Michael Rutherford Helen Huddart Alyshia Mawson Emily Manley Kath Hewitt Jane Coyne Elizabeth Benbow Andrea Crossfield Rachael L Murray Matthew Ev Source Type: research
IJERPH, Vol. 19, Pages 12896: Optimizing the Implementation of Tobacco Treatment for People with HIV: A Pilot Study
M. Rojewski
People with HIV (PWH) have higher rates of tobacco use compared to their societal counterparts and are disproportionately affected by tobacco-related morbidity and mortality. A needs assessment was conducted to assess provider beliefs and opinions on tobacco treatment barriers and treatment approaches. The results highlighted a disconnect between the known importance of quitting smoking and barriers in linking patients to treatment, such as lack of patient interest and other patient issues being a higher priority. Using this assessment data, a treatment delivery approach, Proactive Outreach with Medication ...
Source: International Journal of Environmental Research and Public Health - October 8, 2022 Category: Environmental Health Authors: Madeline G. Foster Benjamin A. Toll Emily Ware Allison Ross Eckard Katherine R. Sterba Alana M. Rojewski Tags: Article Source Type: research
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease
AbstractIncreasing endogenous tear film production via pharmacological neuroactivation of the nasolacrimal reflex [NLR; also known as the trigeminal parasympathetic pathway (TPP)] is a novel therapeutic approach to treating dry eye disease (DED). An intranasal formulation of the water-soluble, small-molecule, nicotinic acetylcholine receptor (nAChR) agonist varenicline (Tyrvaya ™) has been approved in the USA for the treatment of DED. Twice-daily administration of varenicline solution nasal spray resulted in rapid, statistically significant and clinically meaningful improvements in the signs and symptoms of DED over a pe...
Source: Drugs - October 5, 2022 Category: Drugs & Pharmacology Source Type: research
Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review
Compounds known to be successful in the treatment of alcohol use disorder include the aversive agent, Disulfiram, the glutamatergic NMDA receptor antagonist, Acamprosate, and the opioid receptor antagonists, Naltrexone and Nalmefene. Although all four are effective in maintaining abstinence or reduction of alcohol consumption, only a small percentage of patients receive pharmacological treatment. In addition, many other medications have been investigated for their therapeutic potential in the treatment of alcohol use disorder. In this review we summarize and compare Baclofen, Gabapentin, Topiramate, Ondansetron, Vareniclin...
Source: Frontiers in Pharmacology - October 3, 2022 Category: Drugs & Pharmacology Source Type: research
23.4 ADHD Symptoms and Smoking Outcomes in a Randomized Controlled Trial of Varenicline for Adolescent Tobacco Cessation
Many adult daily smokers try their first cigarette during adolescence. ADHD in adolescents has been associated with an increased risk for cigarette smoking in comparison to peers without ADHD. Despite examinations into neurobiological and psychosocial mechanisms underlying this comorbidity, the impact of ADHD on smoking cessation among adolescents has been less well-studied. This presentation will present data from a clinical trial examining ADHD symptoms as a moderator of smoking cessation following varenicline treatment in adolescents. (Source: Journal of the American Academy of Child and Adolescent Psychiatry)
Source: Journal of the American Academy of Child and Adolescent Psychiatry - October 1, 2022 Category: Psychiatry Authors: Rejoyce Green Source Type: research
ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease
Purpose:
The purpose of this trial was to evaluate the safety and efficacy of OC-01 (varenicline solution), a nicotinic acetylcholine receptor agonist nasal spray, on signs and symptoms of dry eye disease.
Methods:
A phase 2b, multicenter, randomized, double-masked, vehicle-controlled trial (ONSET-1; NCT03636061) was performed. Patients were aged 22 years or older with a physician's diagnosis of dry eye disease and previous use of artificial tears were randomized 1:1:1:1 to control (vehicle nasal spray twice daily [BID]), OC-01 0.006 mg BID, OC-01 0.03 mg BID, and OC-01 0.06 mg BID. The primary end point was the...
Source: Cornea - September 18, 2022 Category: Opthalmology Tags: Clinical Science Source Type: research
Which smokers enrol in a hospital based smoking cessation trial? Survey of smoking related behaviours, quit attempts and motivation to quit
CONCLUSIONS: Those who had a prior hospitalisation and were unemployed had significantly greater odds of reporting past quit attempts. Further research is needed to investigate the degree of adherence among inpatient smokers with the smoke-free hospital policies and the frequency of NRT provision and uptake on admission. This article is protected by copyright. All rights reserved.PMID:36065155 | DOI:10.1002/hpja.658 (Source: Health Promotion Journal of Australia)
Source: Health Promotion Journal of Australia - September 6, 2022 Category: International Medicine & Public Health Authors: Rukshar K Gobarani Gregory R Weeks Michael J Abramson Billie Bonevski Eldho Paul Ashley Webb Sue Kirsa Brian J Smith Dennis Thomas Sharmilla Perinpanathan Jacqueline Parkinson Darshana Meanger Lisa Coward Olivia Rofe Paula Lee Johnson George Source Type: research
An evaluation of a New Zealand "vape to quit smoking" programme
CONCLUSIONS: The Te Hā - Waitaha service was successful in engaging Māori in their smoking cessation programme. Nicotine containing e-cigarette products were popular in all cohorts. Nicotine containing e-cigarettes are showing potential in smoking cessation programmes in support of the Smokefree Aotearoa 2025; however, 22% of those in the "vape to quit" programme became dual users.PMID:36049789 (Source: New Zealand Medical Journal)
Source: New Zealand Medical Journal - September 1, 2022 Category: General Medicine Authors: Kelly S Burrowes Chloe Fuge Tori Murray Jonathan Amos Suzanne Pitama Lutz Beckert Source Type: research
